Kansas City Region Launches BioResearch Central

The Kansas Bioscience Authority (KBA) has launched BioResearch Central, a newly formed collaboration of more than 90 CROs and related service providers dedicated to accelerating drug development and medical devices worldwide.
 
BioResearch Central represents an effort by the contract research community in Greater Kansas City to help the pharmaceutical and medical device industries accelerate their pipelines and improve their process for the development of treatments and therapies.
 
“The formation of BioResearch Central helps to reinforce drug and device developers’ recognition that our region is able to meet their outsourcing needs,” said Tom Krol, director of commercialization for the KBA. “We have a diverse network of CROs and service providers in one central location who generate an estimated $1 billion in revenue every year and employ more than 9,000 people. We expect BioResearch Central will facilitate continued growth for this important sector.”
 
The KBA commissioned Tufts University to conduct a study quantifying CRO and related services assets in the Kansas City area and in competing markets nationwide. The study found that the Kansas City region is home to more than 90 CROs and related service providers offering one of the most experienced CRO networks in the country. These CROs support both established companies and startups in the pharmaceutical and medical device industries. The members of BioResearch Central offer a full range of bioresearch services, including discovery, formulation, toxicology, bioanalytics, clinical trials, regulatory and commercial support.